Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDNANASDAQ:CSTLNASDAQ:FLGTNASDAQ:TOI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDNACareDx$15.42+0.2%$17.87$12.90▼$34.84$858.60M2.27870,319 shs1.68 million shsCSTLCastle Biosciences$16.79-2.4%$19.83$15.70▼$35.84$484.76M1.19402,443 shs380,690 shsFLGTFulgent Genetics$19.55+5.3%$17.80$14.57▼$25.11$603.43M1270,920 shs369,014 shsTOIOncology Institute$2.80-4.1%$1.70$0.13▼$3.50$211.57M0.04842,369 shs671,952 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDNACareDx+0.01%+2.80%-19.06%-31.19%+51.47%CSTLCastle Biosciences-2.44%-13.23%-16.51%-39.17%-28.67%FLGTFulgent Genetics+5.33%-4.82%+10.70%+21.13%-8.09%TOIOncology Institute-4.11%0.00%+78.34%+241.46%+204.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDNACareDx3.4703 of 5 stars3.31.00.04.22.70.80.6CSTLCastle Biosciences2.7537 of 5 stars3.54.00.00.02.92.50.0FLGTFulgent Genetics3.3474 of 5 stars2.31.00.04.12.14.20.6TOIOncology Institute0.5546 of 5 stars0.03.00.00.02.51.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDNACareDx 2.57Moderate Buy$30.3396.71% UpsideCSTLCastle Biosciences 3.00Buy$37.50123.35% UpsideFLGTFulgent Genetics 2.50Moderate Buy$24.0022.76% UpsideTOIOncology Institute 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TOI, CDNA, FLGT, and CSTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.005/5/2025CDNACareDxStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$40.00 ➝ $40.005/5/2025CDNACareDxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$25.00 ➝ $25.005/5/2025FLGTFulgent GeneticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.004/17/2025CDNACareDxThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$34.00 ➝ $26.003/28/2025CSTLCastle BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$30.003/4/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$22.00 ➝ $16.003/3/2025CDNACareDxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$26.00 ➝ $25.002/28/2025CSTLCastle BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$36.00 ➝ $37.00(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDNACareDx$346.42M2.48N/AN/A$4.83 per share3.19CSTLCastle Biosciences$347.08M1.40N/AN/A$14.54 per share1.15FLGTFulgent Genetics$292.45M2.06$3.82 per share5.12$38.24 per share0.51TOIOncology Institute$393.41M0.54N/AN/A$0.77 per share3.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDNACareDx-$190.28M$1.15N/AN/AN/A-45.90%-53.70%-30.42%N/ACSTLCastle Biosciences-$57.47M-$0.1983.95N/AN/A1.95%1.47%1.27%N/AFLGTFulgent Genetics-$167.82M-$1.33N/AN/AN/A-59.39%-1.81%-1.66%N/ATOIOncology Institute-$83.07M-$0.71N/A∞N/A-17.63%-186.83%-34.58%5/14/2025 (Estimated)Latest TOI, CDNA, FLGT, and CSTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 million4/30/2025Q1 2025CDNACareDx$0.06$0.09+$0.03-$0.19$84.56 million$84.69 million3/24/2025Q4 2024TOIOncology Institute-$0.08-$0.14-$0.06-$0.14$109.15 million$100.27 million2/26/2025Q4 2024CDNACareDx$0.05$1.51+$1.46$1.51$84.56 million$86.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDNACareDxN/AN/AN/AN/AN/ACSTLCastle BiosciencesN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/ATOIOncology InstituteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDNACareDxN/A4.103.87CSTLCastle Biosciences0.027.787.64FLGTFulgent GeneticsN/A4.414.41TOIOncology Institute5.912.492.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDNACareDxN/ACSTLCastle Biosciences92.60%FLGTFulgent Genetics48.06%TOIOncology Institute36.86%Insider OwnershipCompanyInsider OwnershipCDNACareDx4.90%CSTLCastle Biosciences6.50%FLGTFulgent Genetics33.11%TOIOncology Institute8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDNACareDx74055.68 million51.01 millionOptionableCSTLCastle Biosciences54028.87 million25.99 millionOptionableFLGTFulgent Genetics1,01030.87 million20.87 millionOptionableTOIOncology Institute66075.56 million68.38 millionNot OptionableTOI, CDNA, FLGT, and CSTL HeadlinesRecent News About These CompaniesWhy The Oncology Institute, Inc.’s (TOI) Stock Is Down 5.48%May 10 at 2:10 PM | aaii.comConstellation Software Inc. and Topicus.Com Inc. Announce Results for Topicus.com Inc. for the First Quarter Ended March 31, 2025May 7 at 6:03 PM | globenewswire.comThe Oncology Institute: Insiders Buy Up Big While Valuations Are MurkyMay 6, 2025 | seekingalpha.comWhy The Oncology Institute, Inc.’s (TOI) Stock Is Down 6.07%May 5, 2025 | aaii.comThe Oncology Institute, Inc.'s (NASDAQ:TOI) largest shareholders are retail investors with 40% ownership, private equity firms own 24%May 5, 2025 | uk.finance.yahoo.comTopicus.com Inc. Defers Release Date for First Quarter ResultsMay 1, 2025 | globenewswire.comOncology Institute (NASDAQ:TOI) Stock Price Up 6.3% - Still a Buy?April 26, 2025 | marketbeat.comThe Oncology Institute Announces First Quarter 2025 Earnings Release Date and Conference CallApril 23, 2025 | globenewswire.comTopicus.com Inc. Announces Release Date for First Quarter ResultsApril 14, 2025 | globenewswire.comWhy The Oncology Institute, Inc.’s (TOI) Stock Is Up 9.33%April 10, 2025 | aaii.comWhy The Oncology Institute, Inc.’s (TOI) Stock Is Up 17.46%April 3, 2025 | aaii.comWhy The Oncology Institute, Inc.’s (TOI) Stock Is Up 10.53%April 2, 2025 | aaii.comThe Oncology Institute, Inc. (TOI): Among Stocks Insiders Were Buying In Q1 2025April 1, 2025 | msn.comThe Oncology Institute announces launch of the Florida Oncology NetworkMarch 31, 2025 | markets.businessinsider.comTOI Launches Florida Oncology Network, a Fully Delegated Cancer Care Network, and Announces Four Additional Value-based Contracts in Q1March 31, 2025 | globenewswire.comInsider Buying: The Oncology Institute, Inc. (NASDAQ:TOI) CEO Acquires 22,640 Shares of StockMarch 29, 2025 | insidertrades.comQ4 2024 Oncology Institute Inc Earnings CallMarch 26, 2025 | finance.yahoo.comOncology Institute Full Year 2024 Earnings: US$0.86 loss per share (vs US$0.92 loss in FY 2023)March 26, 2025 | uk.finance.yahoo.comThe oncology institute targets profitability and $460M-$480M revenue in 2025March 25, 2025 | msn.comThe Oncology Institute, Inc. (TOI) Q4 2024 Earnings Call TranscriptMarch 25, 2025 | seekingalpha.comThe Oncology Institute announces $16.5M private placementMarch 24, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTOI, CDNA, FLGT, and CSTL Company DescriptionsCareDx NASDAQ:CDNA$15.42 +0.03 (+0.19%) As of 05/9/2025 03:52 PM EasternCareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Castle Biosciences NASDAQ:CSTL$16.79 -0.42 (-2.44%) As of 05/9/2025 03:59 PM EasternCastle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Fulgent Genetics NASDAQ:FLGT$19.55 +0.99 (+5.33%) As of 05/9/2025 03:52 PM EasternFulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Oncology Institute NASDAQ:TOI$2.80 -0.12 (-4.11%) As of 05/9/2025 04:00 PM EasternThe Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
